Literature DB >> 23932346

Geoepidemiology of primary sclerosing cholangitis: a critical review.

Atsushi Tanaka1, Hajime Takikawa.   

Abstract

Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease of unknown origin, characterized by progressive destruction of bile ducts caused by diffuse inflammation and fibrosis. Previous epidemiological studies in Northern Europe and North America demonstrated that incidence and prevalence rates are ranging from 0.5 to 1.3 and from 3.85 to 16.2 per 100,000 inhabitants per year, respectively. It is of note that the incidence of PSC appears to be gradually increasing. We have extensively reviewed the geoepidemiology of PSC and attempted to place it in context with the incidence in Japan. In 2012, the clinical diagnostic criteria of IgG4-SC were established and published by the Japan Biliary Association, rendering it possible for physicians to clinically differentiate PSC from IgG4-SC. We conducted a new nationwide survey for PSC as well as IgG4-SC, and have identified 197 patients with PSC and 43 patients with IgG4-SC without pancreatic involvement. In this survey we estimated prevalence rate of PSC in Japan as 0.95, lower than those in North America and European countries. Also we identified other unique features of Japanese PSC patients, including 2 peaks in age distribution at diagnosis and fewer presences of comorbid inflammatory bowel diseases, occurring in only 34% of PSC. This data is placed in the perspective of the international experience on PSC.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AIP; CCA; Epidemiology; IBD; IgG4-SCI; IgG4-sclerosing cholangitis; Incidence; PSC; Prevalence; UC; autoimmune pancreatitis; cholangiocarcinoma; gG4-related sclerosing cholangitis; inflammatory bowel diseases; primary sclerosing cholangitis; ulcerative colitis

Mesh:

Year:  2013        PMID: 23932346     DOI: 10.1016/j.jaut.2013.07.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  19 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Adult bile duct strictures: differentiating benign biliary stenosis from cholangiocarcinoma.

Authors:  Hiep Nguyen Canh; Kenichi Harada
Journal:  Med Mol Morphol       Date:  2016-06-27       Impact factor: 2.309

Review 3.  The evolution of natural history of primary sclerosing cholangitis.

Authors:  Will R Takakura; James H Tabibian; Christopher L Bowlus
Journal:  Curr Opin Gastroenterol       Date:  2017-03       Impact factor: 3.287

4.  Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma.

Authors:  F Bernuzzi; F Marabita; A Lleo; M Carbone; M Mirolo; M Marzioni; G Alpini; D Alvaro; K M Boberg; M Locati; G Torzilli; L Rimassa; F Piscaglia; X-S He; C L Bowlus; G-X Yang; M E Gershwin; P Invernizzi
Journal:  Clin Exp Immunol       Date:  2016-05-17       Impact factor: 4.330

Review 5.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

6.  Clinical profile and outcome of primary sclerosing cholangitis: A single-centre experience from western India.

Authors:  Pratik Tibdewal; Pratin Bhatt; Abhinav Jain; Deepak Gupta; Shobna Bhatia; Akash Shukla
Journal:  Indian J Gastroenterol       Date:  2019-09-12

7.  Primary sclerosing cholangitis: A review and update.

Authors:  James H Tabibian; Christopher L Bowlus
Journal:  Liver Res       Date:  2017-12

Review 8.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 9.  Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Authors:  Souvik Sarkar; Christopher L Bowlus
Journal:  Clin Liver Dis       Date:  2015-10-06       Impact factor: 6.126

10.  Factors associated with major radiological progression of primary sclerosing cholangitis in patients with inflammatory bowel disease.

Authors:  Nahla Azzam; Yazed AlRuthia; Othman Alharbi; Abdulrahman Aljebreen; Majid Almadi; Edward V Loftus
Journal:  Hepatol Int       Date:  2020-12-28       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.